Ask AI
ProCE Banner Activity

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

Slideset

Download these slides from a live webinar on current clinical trial data and future directions for novel PROTAC ER degraders in ER+/HER2- MBC, including in patients with ESR1 mutated tumors. 

Released: October 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.